J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial.

The US FDA has cleared BlackfinBio's application for a Phase I/II trial of BFB-101, an AAV gene therapy designed to treat ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

Renibus has completed subject enrolment for the Phase III PROTECT trial of RBT-1 in minimising post-operative risk in cardiac ...

A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.